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History
 The very high-incidence RBC antigen Oka was first de-
scribed by Morel and Hamilton1 in 1979, after the detection 
of clinically significant antibodies in the serum of a Japa-
nese woman (Mrs. S.Ko.G.) who had been admitted to the 
hospital with severe gastrointestinal bleeding. On the ba-
sis of extensive serologic tests, it was shown that the anti-
body was distinct from other antibodies to high-incidence 
or “public” antigens. The antibody was named anti-Oka and 
the antigen Oka after the name of the patient who lacked 
the antigen and developed the antibody. The patient had 
a history of previous blood transfusions but had not been 
pregnant. The patient and her family were from a small is-
land in the Inland Sea off the coast of Honshu in Japan. 
Family studies showed that Oka is inherited. The proband’s 
parents were consanguineous (cousins), and two siblings 
typed Ok(a–) and one sibling typed Ok(a+). Apart from the 
two siblings, no other Ok(a–) individuals were found when 
testing blood samples from more than 400 people living 
on the same island. No Ok(a–) samples were found when 
testing blood samples from a further 870 Japanese indi-
viduals, 1378 Mexican-Americans, 9053 Caucasians, 261 
Asians, 911 Blacks, and 1570 blood donors of undesignated 
ethnicity. Anti-Oka was not detected in the serum of Mrs. 
S.Ko.G.’s compatible sister although she had five children, 
two of whom tested Ok(a+).
 The Ok(a–) phenotype is extremely rare. To date, it has 
been identified in eight families in Japan.2 However, two 
other variants have been identified: anti-Oka was identi-
fied in the plasma of a woman of Iranian background. Her 
RBCs gave variable reactivity with a panel of anti-Oka, indi-
cating that her phenotype was different from that of previ-
ously identified Ok(a–) individuals.3 Second, an antibody 
in the plasma of a prenatal Hispanic woman reacted with 
all RBCs except for three samples of Ok(a–) RBCs. How-
ever, her RBCs were reactive with all anti-Oka tested, again 
indicating a variant phenotype.4 In both cases, molecular 
analysis revealed point mutations in the gene that were 
different from Oka (discussed in more detail later), and 
both have been assigned provisional numbers by the ISBT 
Working Party on Red Cell Immunogenetics and Blood 
Group Terminology.
Nomenclature
There are three RBC antigens in the OK blood group sys-
tem (ISBT 024), Oka (OK1), and the provisionally assigned 
antigens OK2 and OK3. The antigens are located on CD147 
encoded by the gene BSG on chromosome 19p13.3 (Tables 
1 and 2).5,6.
Genetics and Inheritance
 In the original family studies1 two siblings were Ok(a–), 
and one was Ok(a+), showing that Ok is an inherited char-
acteristic on the basis of the serologic tests. Further studies 
by Williams et al.,7 reported in 1988, showed that the Ok de-
terminant is controlled by a single gene OK and that the OK 
locus is on chromosome 19, in the region 19pter-p13.2. Us-
ing the monoclonal antibody TRA-1-85, which they showed 
was specific for the Ok-bearing glycoprotein, these authors 
identified that Oka was carried not only on human RBCs but 
also on leukocytes and on many immortalized human cell 
lines of different tissue origin. Spring et al.6 later demon-
strated that Oka antigen was carried on the M6 leukocyte 
activation antigen (now known as basigin; other synonyms 
EMMPRIN, CD147, TCSF) and identified the point muta-
tion responsible for the Ok(a–) phenotype (see below). 
Using immunohistochemical and Western blotting tech-
niques, the Ok glycoprotein was identified on a wide range 
of tissues.
Molecular Basis
 The gene encoding basigin (BSG) consists of eight exons 
and encodes a type I single-pass transmembrane glycopro-
tein of 269 amino acids. The leader sequence of 21 amino 
acids is cleaved from the mature membrane-bound protein, 
which consists of a glycosylated amino-terminal extracel-
lular domain of 187 amino acids that is arranged into two 
Ig-like subunits and a transmembrane/cytoplasmic domain 
of 40 amino acids. Sequencing of cDNA extracted from three 
Ok(a–) individuals showed a unique missense mutation 274 
G>A in exon 3, which encodes a Glu92Lys substitution in 
the amino-terminal Ig-like subunit of the glycoprotein.6 This 
substitution was shown by transfection studies in murine 
NS-0 cells to be solely responsible for the Ok(a–) phenotype. 
A silent mutation in exon 4 (384T>C) was also identified.
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Table 2. Blood group antigens within the OK system
Antigen number OK1 OK2* OK3*
Antigen name Oka OKGV OKVM
*Provisionally assigned by the ISBT Working Party on Red Cell 
Immunogenetics and Blood Group Terminology (2010 meeting 
report in preparation).
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 The OK:-2 phenotype described in 2003 was shown 
to arise from a nucleotide substitution in exon 2 of BSG: 
176G>T, which encoded the amino acid change Gly59Val.3 
This mutation was found only in the proposita, together 
with two additional silent single-nucleotide exchanges; 
195C>T (Asp65) and 234G>C (Ser78). Interestingly, an ad-
ditional silent transition, 327T>C (Ala108), was identified 
in one of the control samples sequenced in this study. Crew 
and her colleagues also determined the molecular basis of 
the OK:-3 phenotype; sequence analysis of BSG revealed 
another mutation very close by in exon 2, 178G>A, causing 
a Val60Met change in basigin.4
Biochemistry
 As mentioned above, the OK blood group antigens are 
located on basigin (CD147), which is an immunoglobulin 
superfamily glycoprotein having an apparent molecular 
weight on SDS-PAGE of 35,000 to 68,000. It is widely dis-
tributed in human tissues and is present on leukocytes and 
RBCs. Spring and colleagues used the monoclonal antibody 
MA103 to immunopurify the OK glycoprotein.6 MA103 
defines an epitope on the OK glycoprotein but reacts with 
Ok(a–) RBCs. They found that the N-terminal 30 amino ac-
ids were identical to those of the M6 glycoprotein and went 
on to confirm that M6 was the carrier protein for the Oka 
antigen. M6 glycoprotein was also known as the M6 leuko-
cyte activation antigen, basigin (BSG), or the extracellular 
matrix metalloproteinase inducer, EMMPRIN.8
 Extensive studies have been performed on the tissue 
distribution and the role of CD147 in functions such as cell 
adhesion and tumor invasion. Basigin induces the produc-
tion of matrix metalloproteinases in normal fibroblasts as 
well as in tumor cells. It also induces expression of vascular 
endothelial growth factor and hyaluronan and thus stimu-
lates angiogenesis in tumor tissue.9 Basigin has been shown 
to regulate lymphocyte responsiveness, monocarboxylate 
transporter expression, and spermatogenesis, and more re-
cently research has revealed its role as a signaling receptor 
for the extracellular cyclophilin family of proteins.10 It has 
also been reported that basigin facilitates HIV-1 infection 
by an interaction with the virus-associated cyclophilin A on 
the target cell.11
Antibodies in the System
  The first reported anti-Oka (Mrs. S.Ko.G.) was 
detected in a patient who had a history of previous blood 
transfusions, but no history of pregnancy. The anti-Oka was 
determined to be an IgG antibody using the 0.01 M DTT 
test (which differentiates between IgM and IgG antibod-
ies) and was also shown to be monospecific. The titer was 
128 using the antiglobulin technique, and the antibody was 
reactive against both cord and adult RBCs. One other ex-
ample of anti-Oka has been found in Japan.2
 Both OK2 and OK3 antigens were identified by the 
presence of an anti-Oka-like specificity in the plasma of 
both probands, although further examples have not been 
described.
 Despite the paucity of human polyclonal antibodies to 
antigens on CD147, there are monoclonal antibodies that 
detect the protein. The monoclonal anti-Oka TRA-1-185 is 
an IgG1 monoclonal antibody that reacts by the antiglobu-
lin test with all RBC samples tested except Ok(a–) RBCs. 
TRA-1-185 was prepared using spleen cells from a mouse 
immunized with a human teratocarcinoma cell line.
 The monoclonal antibody MA10312 and a number of 
other monoclonal antibodies2 have been produced; these 
antibodies recognize an epitope on the OK glycoprotein and 
react with CD147 but do not have Oka specificity.
 Both human anti-Oka and the monoclonal antibody 
TRA-1-85 react with RBCs that have been pretreated with 
AET, chymotrypsin, neuraminidase, papain, pronase, and 
trypsin.13
 Examples of human Oka antibodies are rare. Three 
novel monoclonal Oka antibodies have been generated that 
may be useful reagents in the laboratory for typing patients’ 
RBCs and for screening donors to find the very rare Ok(a–) 
blood.14
Clinical Significance
 The first example of anti-Oka was clearly shown to be 
of clinical significance. RBC survival studies showed that 
when 10 mL of Ok(a+) whole blood labeled with 51Cr was in-
jected into the patient, only 10 percent of the Ok(a+) RBCs 
survived 3 hours later. The percentage of donor RBCs sur-
viving was reduced to 2 percent at 6 hours.1 In addition, a 
human macrophage assay gave values that correlated with 
antibodies known to cause significant shortening of RBC 
survival.
 There have been no reports of anti-Oka causing hemo-
lytic transfusion reactions or hemolytic disease of the fetus 
and newborn, perhaps not surprising given the rarity of 
the phenotype.
Summary
 The OK blood group system is rarely encountered in 
transfusion medicine because of the high incidence of its 
three antigens and the sparse examples of the correspond-
ing antibodies. The carrier protein basigin, however, is 
widely distributed throughout the body and is functionally 
very important as a signaling molecule in a variety of 
normal and pathogenic processes.
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